3-(Pyrid-2-yl-oxy)-propan-1,2-diol | 1453-90-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(Pyrid-2-yl-oxy)-propan-1,2-diol
• 英文别名: 3--propan-1,2-diol；3-pyridin-2-yloxy-propane-1,2-diol；3-(Pyridin-2-yloxy)propane-1,2-diol；3-pyridin-2-yloxypropane-1,2-diol
• CAS: 1453-90-3
• 化学式: C₈H₁₁NO₃
• 分子量: 169.18
• InChiKey: RXSMKUFIMVNGIR-UHFFFAOYSA-N

物化性质

• 沸点：
  140 °C(Press: 0.08 Torr)
• 密度：
  1.2035 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  62.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(Pyrid-2-yl-oxy)-propan-1,2-diol 在 二异丁基氢化铝 、 三氟乙酸 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 生成 1-Methoxymethoxy-3-(pyridin-2-yloxy)-propan-2-ol
  参考文献：
  名称：

  The preparation of N-alkyl-2(1H)-pyridones by ther reaction of amines with a derivative of 3-(2-pyridyl)propane-1,2-diol

  摘要：

  The reduction of the 2-pyridyl orthoester derivative 7 with DIBAL gives exclusively the secondary alcohol 9 in excellent yield. Mesylation of 9 followed by reaction with amines gives the unusual N-alkyl-2(1H)-pyridones 11 and 12.

  DOI：

  10.1016/s0040-4039(00)74744-7
• 作为产物：
  描述：

  2-溴吡啶 、 甘油 在 copper(l) iodide 、 potassium carbonate 作用下， 反应 6.0h， 以86%的产率得到3-(Pyrid-2-yl-oxy)-propan-1,2-diol
  参考文献：
  名称：

  有氧条件下非无害低共熔溶剂中无配体铜催化乌尔曼型 C−O 键形成

  摘要：

  内在优于外在：芳基烷基醚和有价值的活性药物成分是通过（杂）芳基卤化物和天然存在的醇之间的铜催化乌尔曼型交叉偶联反应获得的，作为环保型氯化胆碱基低共熔混合物的活性成分，在含水和温和的条件下，在没有配体的情况下，并且有效地回收低共熔混合物、催化剂和碱。

  DOI：

  10.1002/cssc.202102211

文献信息

• 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
  申请人：Schnute Edward Mark

  公开号：US20050004161A1

  公开（公告）日：2005-01-06

  The invention provides a compound of formula I: wherein A, B, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The compounds of the present invention are useful for treating viral infections, in particular a herpesviral infection.

  该发明提供了化合物I的结构，其中A、B、R1、R2、R3和R4如规范中定义。本发明的化合物对治疗病毒感染，特别是单纯疱疹病毒感染，具有实用价值。
• Pro-Neurogenic Compounds
  申请人：McKnight Steven L.

  公开号：US20130040977A1

  公开（公告）日：2013-02-14

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生）和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病的治疗方面具有治疗益处，例如精神分裂症、重度抑郁症、躁狂症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性减重，以及与正常衰老、化疗等相关的认知衰退。
• Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds
  申请人：UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS OF THE

  公开号：US20130184271A1

  公开（公告）日：2013-07-18

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  本技术通常涉及化合物和方法，用于刺激神经发生新生（例如，出生后神经发生新生，包括出生后海马和下丘脑神经发生新生）和/或保护神经细胞免受细胞死亡。本文介绍了各种化合物。体内活性测试表明，这些化合物可能在神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、外周神经损伤、与各种疾病相关的生理性体重下降以及与正常衰老、化疗等相关的认知衰退中具有治疗益处。
• Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds
  申请人：OF TEXAS SYSTEM BOARD OF REGENTS OF THE UNIVERSITY

  公开号：US20130190273A1

  公开（公告）日：2013-07-25

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生）和/或保护神经细胞免受细胞死亡的影响。本文披露了各种化合物。体内活性测试表明，这些化合物可能对神经精神疾病和/或神经退行性疾病（如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合症、脊髓小脑性共济失调、肌萎缩性侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、滥用神经活性药物、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性体重减轻以及与正常衰老、化疗等相关的认知衰退）具有治疗益处。
• Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds
  申请人：Board of Regents of The University of Texas System

  公开号：US08735440B2

  公开（公告）日：2014-05-27

  This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

  该技术通常涉及化合物和方法，用于刺激神经发生（例如，产后神经发生，包括产后海马和下丘脑神经发生）和/或保护神经元细胞免受细胞死亡的影响。本文披露了各种化合物。在体内活性测试表明，这些化合物可能对神经精神疾病和/或神经退行性疾病具有治疗效益，例如精神分裂症、重度抑郁症、躁郁症、正常衰老、癫痫、创伤性脑损伤、创伤后应激障碍、帕金森病、阿尔茨海默病、唐氏综合征、脊髓小脑性共济失调、肌萎缩侧索硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用、视网膜退化、脊髓损伤、周围神经损伤、与各种情况相关的生理性体重减轻，以及与正常衰老、化疗等相关的认知衰退。